Secondary infections after cytotoxic chemotherapy in patient with hematological malignancies

Authors

  • Seyit Ali Büyüktuna Cumhuriyet University Faculty of Medicine, Sivas, Turkey
  • Rabin Saba Medstar Antalya Hospital Center, Antalya, Turkey
  • Mustafa Gökhan Gözel Cumhuriyet University Faculty of Medicine, Sivas, Turkey
  • Özge Turhan Akdeniz University Faculty of Medicine, Antalya, Turkey
  • Dilara İnan Akdeniz University Faculty of Medicine, Antalya, Turkey
  • Zahide Aşık Tokat State Hospital, Tokat, Turkey
  • Adem Köse Inonu University Faculty of Medicine, Malatya, Turkey

DOI:

https://doi.org/10.3855/jidc.8530

Keywords:

hematological malignancy, Hematological malignancy, cytotoxic chemotherapy, febrile neutropenia, secondary infection

Abstract

Introduction: This study was initiated to investigate the risk factors of secondary infections in febrile neutropenic patients following chemotherapy, and to evaluate the clinical, microbiological, and mortality outcomes of these infections.

Methodology: An evaluation was done on all patients with hematological malignancy who developed a febrile neutropenic episode (FNE) after cytotoxic chemotherapy in the Department of Hematology, Akdeniz University Faculty of Medicine, between January 2007 and December 2008.

Results: A total of 294 primary FNEs that responded to the initial empirical or targeted treatment were included in the study, and secondary infections developed after 72 (24.5%) of 294 primary FNEs. Risk factors for secondary infections were determined as acute leukemia as the underlying disease, salvage chemotherapy for refractory/relapse diseases, prolonged neutropenia (10 days and over), Multinational Association of Supportive Care in Cancer (MASSC) score < 21, and fungal infection during the primary episode. The mortality rate of patients who developed secondary infections was significantly higher compared to patients without secondary infections (27.8% and 5.4%, respectively; p = 0.001).

Conclusions: The development of secondary infections in patients with hematological malignancy was not very rare. Greater concern should be shown for these infections to increase patient survival rates.

Author Biographies

Seyit Ali Büyüktuna, Cumhuriyet University Faculty of Medicine, Sivas, Turkey

Department of Infectious Diseases and Clinical Microbiology

Rabin Saba, Medstar Antalya Hospital Center, Antalya, Turkey

Department of Infectious Diseases and Clinical Microbiology

Mustafa Gökhan Gözel, Cumhuriyet University Faculty of Medicine, Sivas, Turkey

Department of Infectious Diseases and Clinical Microbiology

Özge Turhan, Akdeniz University Faculty of Medicine, Antalya, Turkey

Department of Infectious Diseases and Clinical Microbiology

Dilara İnan, Akdeniz University Faculty of Medicine, Antalya, Turkey

Department of Infectious Diseases and Clinical Microbiology

Zahide Aşık, Tokat State Hospital, Tokat, Turkey

Department of Infectious Diseases and Clinical Microbiology

Adem Köse, Inonu University Faculty of Medicine, Malatya, Turkey

Department of Infectious Diseases and Clinical Microbiology

Downloads

Published

2017-07-31

How to Cite

1.
Büyüktuna SA, Saba R, Gözel MG, Turhan Özge, İnan D, Aşık Z, Köse A (2017) Secondary infections after cytotoxic chemotherapy in patient with hematological malignancies. J Infect Dev Ctries 11:521–526. doi: 10.3855/jidc.8530

Issue

Section

Original Articles